Milestone Pharmaceuticals Inc

NASDAQ:MIST  
5.76
+0.20 (+3.60%)
Earnings Announcements

Milestone Pharmaceuticals Reports Fourth Quarter And Full Year 2020 Financial Results

Published: 03/29/2021 21:48 GMT
Milestone Pharmaceuticals Inc (MIST) - Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update.
Milestone Pharmaceuticals Inc Qtrly Loss per Share $0.23.
Milestone Pharma - Believes Cash, Cash Equivalents, Short-term Investments Will Be Sufficient to Fund Anticipated Operating Expenses Through 2022.
Milestone Pharma - Believes Current Cash, Cash Equivalents, Short-term Investments Will Be Sufficient to Fund Anticipated Capex Needs Through 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.33

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.36

More details on our Analysts Page.